(Q36989921)

17 August 2017

1 reference

title

Emerging drugs for biliary cancer (English)

1 reference

17 August 2017

Florian Eckel

1

1 reference

17 August 2017

Roland M Schmid

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Emerging Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

12

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

571-589

1 reference

17 August 2017

cites work

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Epidemiology and molecular pathology of gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Gallbladder cancer worldwide: geographical distribution and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

The molecular pathogenesis of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Phase II study of S-1 in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Targeting death-inducing receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Acute experimental pancreatitis and NF-kappaB/Rel activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Interleukin-6 trans-signalling in chronic inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Expression of human telomerase catalytic protein in gallbladder carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.571

10.1517/14728214.12.4.571

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference